As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.

Step into leadership. Learn how to apply for the AMCP Board of Directors and help shape the future of managed care pharmacy.

Yesterday, the Senate Health, Education, Labor, and Pensions (HELP) Committee released the text and a section-by-section summary of its portion of the reconciliation bill. The package focuses largely on higher education, targeting financial assistance programs that Republicans allege inflate tuition costs at colleges and universities. While the committee adjusted certain policies in the One Big, Beautiful Bill Act (H.R. 1), the House’s version of reconciliation that passed last month, the draft bill leaves two policies that AMCP is tracking untouched.

Removal of all members of ACIP at the Centers for Disease Control & Prevention (CDC) is nothing short of alarming. Vaccines are a vital component of American public health infrastructure, and their safety and efficacy is well-established by reliable clinical evidence. Pharmacists, including AMCP members, provide patients with vaccines that prevent serious illness, hospitalizations, and even death. In many states, pharmacists’ ability to administer these life-saving vaccines are tied to ACIP recommendations.

In this compelling and educational video, Lindsey Sullivan shares her personal journey with alopecia areata, offering valuable insights into the emotional and clinical aspects of living with this autoimmune condition. As both a patient and advocate, Lindsey sheds light on the challenges of diagnosis, treatment decisions, and navigating the healthcare system.

Last week, over 450 health and technology leaders convened in a packed DC conference center for a morning summit on the present and future of Artificial Intelligence (AI) hosted by the DC Tech & Venture Coalition (DCTAV), a coalition of executives, entrepreneurs, and investors dedicated to improving the District of Columbia’s role as a hub of technology and capital.

AMCP strongly supports the passage of the MVP Act. Medicaid beneficiaries are among America's most vulnerable patients. Value-based payment arrangements are a critical tool for promoting patient access to high-quality, affordable care.

AMCP supports the Ensuring Community Access to Pharmacist Services Act. This bill will help ensure that Americans can continue to rely on pharmacists as essential partners in pandemic preparedness and response. The ECAPS Act will also improve patient access to tests and treatments by authorizing pharmacists to provide these services and receive reimbursement under Medicare Part B. The ECAPS Act addresses disparities in public health preparedness in medically underserved communities like rural areas by allowing these patients to seek care from their most accessible provider.

AMCP supports the Access to Prescription Digital Therapeutics Act. Expanding coverage of PDTs will improve care for millions of American patients and help standardize reimbursement practices and coding of these therapies across both public and private payers.

State legislatures across the country have introduced bills designed to regulate the use of artificial intelligence (AI) systems by health care entities.